EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudieOpen Access · CC BY 4.0

Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study

Gregorio Spagni iD, Massimiliano Ugo Verza, Sara Cornacchini, Francesca Beretta, Bo Sun, Antonio Lotti, Silvia Falso, Alessandro Barilaro, Luca Massacesi, Amelia Evoli iD, Valentina Damato

European Journal of Neurology · 2025-06 · 32 (6)

DOI: 10.1111/ene.70262 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 25.06.2025. Verfasst von Gregorio Spagni und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Myasthenia Gravis, Patient Reported Outcome Measures. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, the Myasthenia Gravis Rare Disease Network-MGNet, NIHR Academic Clinical Lectureship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patient Acceptable Symptom State (PASS) is emerging as a valuable subjective measure of the overall myasthenia gravis (MG)‐related burden. This study aimed at identifying PASS‐positive thresholds for the most used clinical scales, investigating whether PASS and MGFA post‐intervention status capture different aspects of the disease outcome, and identifying clinical variables associated with PASS=YES response.

Methods

Adult AChR‐MG patients were prospectively enrolled at two Italian Centres (Rome: index cohort; Florence: validation cohort). PASS thresholds for MG‐ADL, QMG, and MG‐QOL15r were defined in the index cohort by ROC analysis and validated in the validation cohort; predictors of favorable PASS were identified by multivariable analysis.

Results

This study included 173 patients (44% females, median age at onset: 53 years). PASS=YES patients had significantly lower median MG‐ADL, QMG, and MG‐QOL15r scores, with the following thresholds for PASS=YES: MG ADL ≤ 2, QMG ≤ 8 and MG‐QOL15r ≤ 6. The MG‐ADL (OR = 0.46, 95% CI = 0.36–0.60, p < 0.001), QMG (OR = 0.72, 95% CI = 0.64–0.81, p < 0.001) and MG‐QOL15r (OR = 0.76, 95% CI = 0.70–0.84, p < 0.001), were independently associated with a favorable PASS. The degree of ocular involvement in each scale was the strongest negative determinant of PASS=YES.

Conclusions

This study validates the PASS question and highlights the relevance of ocular complaints in patients' perception of MG burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisPatient Reported Outcome MeasuresHumansFemaleMaleMiddle AgedAdultProspective StudiesAgedQuality of Life

Stichwörter der Autor:innen

myasthenia gravisocular symptomsoutcomepatient‐acceptable symptom statepatient‐reported outcome measuresquality of life

Autor:innen und Institutionen

  • Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
  • Department of Neurosciences and Sensory Organs, Careggi University Hospital, Florence, Italy.
  • Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Department of Neurosciences, Catholic University of the Sacred Hearth, Rome, Italy.

ORCID-Profile: Gregorio Spagni, Amelia Evoli

Förderung

  • NCATS NIH HHS
  • the Myasthenia Gravis Rare Disease Network-MGNet
  • NIHR Academic Clinical Lectureship
  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • Italian Ministry of Health
  • NINDS NIH HHS
  • Ministero della Salute

Zitieren

APA

Spagni, G., Verza, M. U., Cornacchini, S., Beretta, F., Sun, B., Lotti, A., Falso, S., Barilaro, A., Massacesi, L., Evoli, A., & Damato, V. (2025). Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study. European Journal of Neurology, 32(6). https://doi.org/10.1111/ene.70262

Vancouver

Spagni G, Verza MU, Cornacchini S, Beretta F, Sun B, Lotti A, et al. Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study. European Journal of Neurology. 2025;32(6). doi:10.1111/ene.70262

BibTeX
@article{Spagni2025,
  author = {Spagni, Gregorio and Verza, Massimiliano Ugo and Cornacchini, Sara and Beretta, Francesca and Sun, Bo and Lotti, Antonio and Falso, Silvia and Barilaro, Alessandro and Massacesi, Luca and Evoli, Amelia and Damato, Valentina},
  title = {Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {6},
  doi = {10.1111/ene.70262}
}
Kostenlos starten →